Oncology drugs are clearly the focus of development going into the future, while drugs for infectious disease and central nervous system also make up a large proportion of R&D spend.
Figure 1: Number of pipeline drugs in the US, by therapy area
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
Source: GlobalData, Pharma Intelligence Center, Drug Database [Accessed 1 November 2017]
GlobalData Strategic Intelligence
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData